CA2983276A1 - Polypeptides targeting hiv fusion - Google Patents
Polypeptides targeting hiv fusion Download PDFInfo
- Publication number
- CA2983276A1 CA2983276A1 CA2983276A CA2983276A CA2983276A1 CA 2983276 A1 CA2983276 A1 CA 2983276A1 CA 2983276 A CA2983276 A CA 2983276A CA 2983276 A CA2983276 A CA 2983276A CA 2983276 A1 CA2983276 A1 CA 2983276A1
- Authority
- CA
- Canada
- Prior art keywords
- polypeptide
- seq
- amino acid
- adnectin
- moiety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Immunology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562152271P | 2015-04-24 | 2015-04-24 | |
| US62/152,271 | 2015-04-24 | ||
| US201562257474P | 2015-11-19 | 2015-11-19 | |
| US62/257,474 | 2015-11-19 | ||
| PCT/US2016/027424 WO2016171980A1 (en) | 2015-04-24 | 2016-04-14 | Polypeptides targeting hiv fusion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2983276A1 true CA2983276A1 (en) | 2016-10-27 |
Family
ID=55809237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2983276A Abandoned CA2983276A1 (en) | 2015-04-24 | 2016-04-14 | Polypeptides targeting hiv fusion |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US10407490B2 (https=) |
| EP (2) | EP3985020A1 (https=) |
| JP (3) | JP6894846B2 (https=) |
| KR (1) | KR20170138558A (https=) |
| CN (1) | CN107922474A (https=) |
| AU (2) | AU2016252008B2 (https=) |
| BR (1) | BR112017022790A2 (https=) |
| CA (1) | CA2983276A1 (https=) |
| CL (1) | CL2017002687A1 (https=) |
| CO (1) | CO2017011583A2 (https=) |
| CR (1) | CR20170482A (https=) |
| DO (1) | DOP2017000246A (https=) |
| EA (1) | EA035332B1 (https=) |
| ES (1) | ES2884267T3 (https=) |
| HK (1) | HK1243432A1 (https=) |
| IL (1) | IL255122A0 (https=) |
| MA (2) | MA56222A (https=) |
| MX (1) | MX2017013687A (https=) |
| PE (1) | PE20180162A1 (https=) |
| PH (1) | PH12017501914A1 (https=) |
| PT (1) | PT3286212T (https=) |
| SG (1) | SG11201708441RA (https=) |
| TW (1) | TW201643185A (https=) |
| UY (1) | UY36650A (https=) |
| WO (1) | WO2016171980A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106755100A (zh) * | 2017-02-20 | 2017-05-31 | 李因传 | 可控性hiv‑1基因组靶向编辑系统和其靶向载运系统 |
| JP2021507717A (ja) * | 2017-12-18 | 2021-02-25 | ビーブ、ヘルスケア、ユーケー、（ナンバー５）、リミテッドＶｉｉｖ Ｈｅａｌｔｈｃａｒｅ Ｕｋ （Ｎｏ．５） Ｌｉｍｉｔｅｄ | 抗原結合性ポリペプチド |
| CN108997482B (zh) * | 2018-08-09 | 2025-09-09 | 东莞市朋志生物科技有限公司 | 用于检测hiv-1的合成肽 |
| WO2021081515A2 (en) * | 2019-10-25 | 2021-04-29 | Cidara Therapeutics, Inc. | Compositions and methods for the treatment of human immunodeficiency virus |
| EP4397748A4 (en) * | 2021-08-30 | 2025-09-17 | Kanglin Biotechnology Hangzhou Co Ltd | GENE SEQUENCE CONSTRUCTION FOR GENE THERAPY AGAINST HIV INFECTION |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US5672502A (en) | 1985-06-28 | 1997-09-30 | Celltech Therapeutics Limited | Animal cell culture |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| US6048728A (en) | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| JP3051145B2 (ja) | 1990-08-28 | 2000-06-12 | 住友製薬株式会社 | 新規なポリエチレングリコール誘導体修飾ペプチド |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| MD1367C2 (ro) | 1992-11-13 | 2000-11-30 | Idec Pharmaceuticals Corporation | Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom. |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US6261804B1 (en) | 1997-01-21 | 2001-07-17 | The General Hospital Corporation | Selection of proteins using RNA-protein fusions |
| DK1712623T3 (da) | 1997-01-21 | 2012-02-06 | Gen Hospital Corp | Udvælgelse af proteiner ved anvendelse af RNA-proteinfusioner |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| AU2265701A (en) * | 1999-12-16 | 2001-06-25 | Tanox, Inc. | Anti-hiv-1 conjugates for treatment of hiv disease |
| US20050287153A1 (en) | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
| CA2416219C (en) | 2000-07-11 | 2016-10-11 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| EP1543166A4 (en) * | 2002-09-27 | 2009-10-28 | Genentech Inc | SYNERGETIC COMPOSITIONS FOR PREVENTING AND TREATING THE ACQUIRED IMMUNE WEAKNESS SYNDROME |
| ES2655912T3 (es) | 2002-11-08 | 2018-02-22 | Ablynx N.V. | Anticuerpos de dominio simple dirigidos contra factor de necrosis tumoral-alfa y usos para los mismos |
| ES2567634T3 (es) | 2004-02-09 | 2016-04-25 | Human Genome Sciences, Inc. | Proteínas de fusión de albúmina |
| US20070269422A1 (en) | 2006-05-17 | 2007-11-22 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| US20090022720A1 (en) * | 2007-07-20 | 2009-01-22 | Stephan Fischer | Conjugate of an antibody against CD4 and antifusogenic peptides |
| JP2011507543A (ja) | 2007-12-27 | 2011-03-10 | ノバルティス アーゲー | 改善されたフィブロネクチンベースの結合分子およびそれらの使用 |
| PL2274331T3 (pl) | 2008-05-02 | 2014-04-30 | Novartis Ag | Ulepszone cząsteczki wiążące oparte na fibronektynie i ich zastosowanie |
| BRPI0919881B1 (pt) * | 2008-10-31 | 2021-09-08 | Centocor Ortho Biotech Inc | Proteína de arcabouço e seu método de geração, biblioteca e seu método de construção, molécula de ácido nucleico, vetor de ácido nucleico, célula hospedeira, composição, dispositivo médico e artigo de fabricação |
| GB0920944D0 (en) * | 2009-11-30 | 2010-01-13 | Biotest Ag | Agents for treating disease |
| EP2516459A1 (en) * | 2009-12-22 | 2012-10-31 | Aarhus Universitet (University Of Aarhus) | Bivalent molecules for hiv entry inhibition |
| EA022983B1 (ru) * | 2010-04-13 | 2016-04-29 | Бристол-Майерс Сквибб Компани | Белки на основе структурного домена фибронектина, связывающие pcsk9 |
| TW201138808A (en) * | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
| RU2012148816A (ru) * | 2010-05-07 | 2014-06-20 | Ф. Хоффманн-Ля Рош Аг | Метод диагностики для определения клеток ex vivo |
| JP2014504587A (ja) * | 2010-12-22 | 2014-02-24 | ブリストル−マイヤーズ スクイブ カンパニー | Ｉｌ−２３に結合するフィブロネクチンをベースとするスカフォールドドメインタンパク質 |
| AU2012260434A1 (en) * | 2011-05-23 | 2013-10-31 | Phylogica Limited | Method of determining, identifying or isolating cell-penetrating peptides |
| EP2761066B1 (en) * | 2011-09-27 | 2018-12-05 | Janssen Biotech, Inc. | Fibronectin type iii repeat based protein scaffolds with alternative binding surfaces |
| EP2951206A2 (en) * | 2013-02-01 | 2015-12-09 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins |
| US20160152686A1 (en) * | 2013-03-13 | 2016-06-02 | Bristol-Myers Squibb Company | Fibronectin based scaffold domains linked to serum albumin or moiety binding thereto |
| CN103333255A (zh) * | 2013-06-28 | 2013-10-02 | 复旦大学 | 一种长效hiv‐1膜融合抑制剂 |
-
2016
- 2016-04-14 US US15/568,830 patent/US10407490B2/en active Active
- 2016-04-14 CR CR20170482A patent/CR20170482A/es unknown
- 2016-04-14 AU AU2016252008A patent/AU2016252008B2/en not_active Ceased
- 2016-04-14 MA MA056222A patent/MA56222A/fr unknown
- 2016-04-14 MA MA041943A patent/MA41943A/fr unknown
- 2016-04-14 MX MX2017013687A patent/MX2017013687A/es unknown
- 2016-04-14 CN CN201680036930.XA patent/CN107922474A/zh active Pending
- 2016-04-14 PT PT167188176T patent/PT3286212T/pt unknown
- 2016-04-14 EA EA201792269A patent/EA035332B1/ru not_active IP Right Cessation
- 2016-04-14 PE PE2017002311A patent/PE20180162A1/es unknown
- 2016-04-14 KR KR1020177033985A patent/KR20170138558A/ko not_active Withdrawn
- 2016-04-14 WO PCT/US2016/027424 patent/WO2016171980A1/en not_active Ceased
- 2016-04-14 HK HK18102882.7A patent/HK1243432A1/zh unknown
- 2016-04-14 EP EP21176464.2A patent/EP3985020A1/en not_active Withdrawn
- 2016-04-14 JP JP2017555557A patent/JP6894846B2/ja not_active Expired - Fee Related
- 2016-04-14 ES ES16718817T patent/ES2884267T3/es active Active
- 2016-04-14 CA CA2983276A patent/CA2983276A1/en not_active Abandoned
- 2016-04-14 BR BR112017022790-8A patent/BR112017022790A2/pt not_active IP Right Cessation
- 2016-04-14 SG SG11201708441RA patent/SG11201708441RA/en unknown
- 2016-04-14 EP EP16718817.6A patent/EP3286212B1/en active Active
- 2016-04-22 UY UY0001036650A patent/UY36650A/es not_active Application Discontinuation
- 2016-04-22 TW TW105112708A patent/TW201643185A/zh unknown
-
2017
- 2017-10-18 IL IL255122A patent/IL255122A0/en unknown
- 2017-10-19 PH PH12017501914A patent/PH12017501914A1/en unknown
- 2017-10-23 CL CL2017002687A patent/CL2017002687A1/es unknown
- 2017-10-23 DO DO2017000246A patent/DOP2017000246A/es unknown
- 2017-11-14 CO CONC2017/0011583A patent/CO2017011583A2/es unknown
-
2019
- 2019-08-07 US US16/533,941 patent/US11155602B2/en active Active
- 2019-09-06 AU AU2019226255A patent/AU2019226255A1/en not_active Abandoned
-
2020
- 2020-10-16 JP JP2020174288A patent/JP2021035951A/ja active Pending
-
2023
- 2023-02-03 JP JP2023014947A patent/JP7465378B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11155602B2 (en) | Polypeptides targeting HIV fusion | |
| US11161893B2 (en) | Fibronectin based scaffold proteins having improved stability | |
| DK2697257T3 (en) | FC FUSION PROTEINS INCLUDING UNKNOWN LINKERS OR EVENTS | |
| WO2011103105A1 (en) | Fibronectin based scaffold domain proteins that bind il-23 | |
| EP2968587A2 (en) | Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto | |
| IL270110B (en) | Proteins based on the scaffolding domain of fibronectin that bind to myostatin | |
| Meng et al. | Design and biological evaluation of m-xylene Thioether-stapled short helical peptides targeting the HIV-1 gp41 Hexameric coiled–coil fusion complex | |
| US20240239877A1 (en) | Antigen binding polypeptides | |
| CN118510536A (zh) | 松弛素-2融合蛋白类似物及其使用方法 | |
| Egerer et al. | The Prevention of HIV Infection with Viral Entry Inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20220705 |